Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Operating Leases (2020 - 2025)

Historic Operating Leases for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $56.3 million.

  • TScan Therapeutics' Operating Leases rose 88.33% to $56.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 88.33%. This contributed to the annual value of $60.7 million for FY2024, which is 270.38% up from last year.
  • TScan Therapeutics' Operating Leases amounted to $56.3 million in Q3 2025, which was up 88.33% from $58.1 million recorded in Q2 2025.
  • TScan Therapeutics' 5-year Operating Leases high stood at $60.7 million for Q4 2024, and its period low was $3.0 million during Q3 2022.
  • Over the past 5 years, TScan Therapeutics' median Operating Leases value was $53.4 million (recorded in 2022), while the average stood at $39.0 million.
  • Per our database at Business Quant, TScan Therapeutics' Operating Leases crashed by 3673.55% in 2022 and then soared by 163744.64% in 2023.
  • TScan Therapeutics' Operating Leases (Quarter) stood at $4.4 million in 2021, then skyrocketed by 1107.04% to $53.0 million in 2022, then rose by 11.56% to $59.1 million in 2023, then rose by 2.7% to $60.7 million in 2024, then fell by 7.3% to $56.3 million in 2025.
  • Its last three reported values are $56.3 million in Q3 2025, $58.1 million for Q2 2025, and $59.9 million during Q1 2025.